immunity News and Research

RSS

IL-2 compound ineffective against HIV-AIDS

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped.

19 Oct 2009

More nutrition guidance needed to build good eating habits in growing children, says Nestle FITS survey

Parents and caregivers are hearing and following the feeding guidance for infants, yet continued work needs to be done to help them also build good eating habits for their growing children, suggests data from the Nestle Feeding Infants and Toddlers Study (FITS) released today at a symposium at the American Dietetic Association's Food & Nutrition Conference & Expo.

19 Oct 2009

Novel HIV drug to be studied in cell cultures and patients

A $6 million, five-year federal grant to The Children's Hospital of Philadelphia Research Institute will enable researchers to investigate a novel approach in treating HIV infection---a unique class of drugs focused on developing therapies for psychological and neurological effects in AIDS.

19 Oct 2009

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

19 Oct 2009

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

The National Institutes of Health has awarded a $15.7 million contract to UT Southwestern Medical Center and Northrop Grumman Corp. to develop an open-access national online database and analysis resource center that will help scientists study and combat viruses such as those that cause hepatitis, encephalitis, smallpox, acute respiratory distress and dengue fever, as well as newly emerging pathogenic viruses.

15 Oct 2009

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

University of California, Davis, researchers studying the 2009 H1N1 influenza virus, formerly referred to as "swine flu," have identified a group of immunologically important sites on the virus that are also present in seasonal flu viruses that have been circulating for years. These molecular sites appear to result in some level of immunity to the new virus in people who were exposed to the earlier influenza viruses.

15 Oct 2009

Required flu vaccines for New York health workers draws criticism

The New York Civil Liberties Union is criticizing a regulation that requires hundreds of thousands of state health workers to get both seasonal and swine flu vaccinations. Critics say it violates workers' right to decide their own medical treatment.

15 Oct 2009

Government of Canada to support H1N1 flu virus research

The Government of Canada through the Canadian Institutes of Health Research (CIHR) today announced support for five new research projects designed to help further understand and address the H1N1 flu virus.

15 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

Early action, especially rapid rollout of vaccines, is extremely effective in reducing the attack rate of the H1N1 influenza virus, according to a simulation model of a pandemic outbreak reported in a new study in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

14 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Fight against obesity and heart disease gets new boost from public sector and industry

The battle against obesity, heart disease and other diet related health problems received a -4 Million boost today with the announcement of seven new research projects. The projects, taking place in universities and research institutes across the UK, are part of a partnership between two publicly-funded Research Councils and 15 companies.

9 Oct 2009

NIAID awards $60M for research contracts to discover new adjuvants

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded six new research contracts to discover and characterize novel adjuvants, substances that can be added to vaccines to enhance the protective immune response they induce.

9 Oct 2009

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

St. Jude Children's Research Hospital investigators have discovered how destructive immune cells gain access to insulin-producing cells and help cause diabetes.

9 Oct 2009

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

Pre-registered and certified providers in the southwest, southeast, and north-central regions of the state have begun to receive the first doses of the live attenuated pandemic H1N1 influenza vaccine, also known by the brand name FluMist, the Pennsylvania Department of Health said today.

7 Oct 2009

New line of supplement products from Innovative Beverage Products

Amidst the cluttered counters within stores across the nation that contain countless copycat and unimaginative energy shots comes a new healthy twist and spark of vitality to the shot category. HealthShots(TM) - a new product line fortified with a host of healthy blends formulated specifically to taste great while also providing functional ingredients based on health and wellness concerns - has just launched in Long Island.

7 Oct 2009

Vivaldi receives US patent for live attenuated influenza vaccines

Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.

6 Oct 2009

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects. The work may provide new targets for boosting immune system function in older individuals.

6 Oct 2009

Key defence mechanism used by the immune system against Listeria identified

A team of University of British Columbia microbiologists has identified a key defence mechanism used by the immune system against Listeria with strong implications for the future development of vaccines.

6 Oct 2009

Majority of Europeans not concerned about H1N1

Three quarters of European people surveyed between the 30th April and 6th May 2009 said they were either not at all concerned or only a little concerned about swine flu.

6 Oct 2009

immunity News and Research

IL-2 compound ineffective against HIV-AIDS

More nutrition guidance needed to build good eating habits in growing children, says Nestle FITS survey

Novel HIV drug to be studied in cell cultures and patients

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

Required flu vaccines for New York health workers draws criticism

Government of Canada to support H1N1 flu virus research

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

Fight against obesity and heart disease gets new boost from public sector and industry

NIAID awards $60M for research contracts to discover new adjuvants

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

New line of supplement products from Innovative Beverage Products

Vivaldi receives US patent for live attenuated influenza vaccines

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

Key defence mechanism used by the immune system against Listeria identified

Majority of Europeans not concerned about H1N1

Industry Focus eBook - Cell biology (5th edition) eBook

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News